Researchers identify T-cell subsets as effective therapeutic target for preventing transplant rejection

Houston Methodist researchers identified a troublesome subset of T-cells in transplant recipients that may be a more effective therapeutic target for preventing transplant rejection in patients.

Each day, 17 people die waiting for organ CD4+ T cell immunity is dependent on an intrinsic stem-like program" in a recent issue of Nature Immunology, a multidisciplinary journal that publishes papers with insight into the workings of the immune system.

Wenhao Chen, Ph.D., associate professor of transplant immunology with the Houston Methodist Research Institute, and his team used single-cell RNA sequencing to analyze the CD4+ T-cell response in transplantation scenarios and identified a subset that he referred to as "troublemakers." They also discovered the mechanism behind what directs that T-cell response in animal transplant models.

This troublesome subset of CD4+ T-cells they discovered acts like stem cells and continuously generates functionally mature effector T-cells that attack transplanted organs. They also found that the transcription factor IRF4 is required for T-cells in that subset to become those organ-attacking effector T-cells. Thus, Chen says IRF4 is what needs to be targeted to solve the problem of transplant rejection or to develop an autoimmunity cure.

"T-cells play a central role in fighting infections and cancer, but they are also the key players in mediating autoimmune diseases and transplant rejection," Chen said. "Our study demonstrated that IRF4 is a master regulator of T-cell function; a discovery that will allow the development of innovative therapies for patients with chronic infections, cancers, autoimmune diseases, and transplanted organs."

Eliminating undesired CD4+ T-cell responses that could potentially lead to the loss of transplanted organs could eventually apply to all transplant patients, he said of this discovery.

"How to therapeutically inhibit IRF4 is the Nobel-prize winning question," Chen said in reference to a past research study on this challenge. "If we can find a way to inhibit IRF4 as desired in activated T-cells, then I think most autoimmune diseases and transplant rejection will be solved."

Their findings are described in an article titled "CD4+ T cell immunity is dependent on an intrinsic stem-like program" in a recent issue of Nature Immunology.

This revelation about the true troublemaker within the CD4+ T-cell population is just the tip of the iceberg. I sincerely hope our findings garner widespread attention, motivating both researchers and patients to recognize the significance of targeting these troublemakers."

Wenhao Chen, Ph.D., associate professor of transplant immunology, Houston Methodist Research Institute

Researchers collaborating with Chen on this multidisciplinary effort from the Immunobiology & Transplant Science Center at the Houston Methodist Research Institute include Dawei Zou, Guohua Wang, Yang Guo, Xiang Xiao, Xiaolong Zhang, Nancy M. Gonzalez, Laurie J. Minze and Xian C. Li; Zheng Yin, Lin Wang and Stephen T.C. Wong from the Systems Medicine and Bioengineering Department with the Houston Methodist Neal Cancer Center; Stephanie G. Yi, A. Osama Gaber and Rafik M. Ghobrial from the Department of Surgery in the J. C. Walter Jr. Transplant Center at Houston Methodist Hospital; and Shuang Li from the Center for Neuroregeneration at the Houston Methodist Research Institute.

The study was supported by internal funding from Houston Methodist Research Institute and U.S. National Institutes of Health (grants R01 AI132492 and R01 AI129906).

Journal reference:

Zou, D., et al. (2024). CD4+ T cell immunity is dependent on an intrinsic stem-like program. Nature Immunology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers identify a potential metabolic target for cancer immunotherapy